ReviewFrontiers in bioengineering and biotechnology2026
Chitosan in regenerative medicine: a translational perspective on biomaterial design.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitosan is an aminopolysaccharide platform with broad relevance to regenerative medicine because its charge density, solubility, degradation, processability, and biological interactions can be adjusted through source selection, deacetylation chemistry, molecular-weight control, derivatization, and formulation. However, this tunability is accompanied by substantial source- and process-dependent variability, which represents a central translational challenge: materials labelled as chitosan can differ markedly in degree of deacetylation, molecular weight, pattern of acetylation, polydispersity, purity, endotoxin and β-glucan burden, residual reagents, sterilization history, and final architecture. This review synthesizes chitosan regenerative biomaterials from a translational design perspective. We examine raw-material provenance, crustacean and fungal sources, extraction and deacetylation routes, physicochemical determinants, medical-grade purity requirements, host-biointerface mechanisms, antimicrobial activity, scaffolds, hydrogels, coatings, bioinks, polymer composites, and functionalization with growth factors, drugs, peptides, and extracellular vesicles. We also address ethical, cell-related, regulatory, and manufacturing issues that arise when chitosan is combined with animal-derived inputs, antibiotics, growth factors, living cells, or extracellular-vesicle preparations. Across applications, the evidence indicates that chitosan should not be treated as a universally biocompatible, universally antimicrobial, or intrinsically regenerative polymer. Rather, it is a tunable, formulation-dependent biomaterial platform whose performance depends on defined chemical attributes, exposure route, biological context, and clinically relevant comparators. Translation will require standardized reporting of degree of deacetylation, molecular weight, acetylation pattern, purity, endotoxin and β-glucan controls, sterilization effects, degradation, release kinetics, post-release bioactivity, and product-specific biological evaluation. Regulatory-aware design, reproducible manufacturing, and mechanism-linked potency assays are essential for moving chitosan-based regenerative systems from promising preclinical constructs toward credible clinical products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.